Home › Funds › Opaleye Management Inc. › ZNTL
Opaleye Management Inc. position in ZNTL
ZENTALIS PHARMACEUTICALS INC · Health Care
Opaleye Management Inc. reported holding 1,412,656 shares of ZNTL (ZENTALIS PHARMACEUTICALS INC) in its Q2 2026 13F filing — a position valued at US$6.9M, representing 0.62% of its reported portfolio and ranking #30 among its reported holdings. Opaleye Management Inc. has disclosed ZNTL holdings in 9 of the last 10 reported quarters, going back to Q1 2024.
Last updated: 2026-10-24 · Source: SEC EDGAR Form 13F-HR
How Opaleye Management Inc.'s ZNTL position evolved
Opaleye Management Inc. first disclosed a stake in ZNTL in Q1 2024 at 200,000 shares (US$3.2M). The position peaked in Q2 2026 at 1,412,656 shares, worth US$6.9M. Across 9 filings, Opaleye Management Inc. increased the stake 4 time(s), trimmed it 2 time(s) and left it unchanged 1 time(s). The most recent filing (Q2 2026) shows 1,412,656 shares valued at US$6.9M. Notable position changes include a 83% increase in Q4 2024 (shares fell 48% over the following quarter), a 84% trim in Q3 2025 (shares fell 11% over the following quarter), a 343% increase in Q4 2025 (shares rose 73% over the following quarter).
Quarter by quarter
| Quarter | Shares | Value | Change |
|---|---|---|---|
| Q1 2024 | 200.00K | $3.15M | New |
| Q3 2024 | 967.00K | $3.56M | New |
| Q4 2024 | 1.77M | $5.36M | Add |
| Q1 2025 | 1.99M | $3.16M | Add |
| Q2 2025 | 1.92M | $2.23M | Reduce |
| Q3 2025 | 316.55K | $477.99K | Reduce |
| Q4 2025 | 1.40M | $1.89M | Add |
| Q1 2026 | 1.41M | $3.31M | Add |
| Q2 2026 | 1.41M | $6.85M | Hold |
Dots on the line are colored by change type; missing quarters mean no position was reported.
About ZNTL and 13F data
ZNTL (ZENTALIS PHARMACEUTICALS INC) is a Health Care company. 29 other funds we track also report a position in ZNTL — the largest reported positions include 5AM Venture Management, LLC (US$19.1M), Decheng Capital LLC (US$6.4M), Ishara Investments LP (US$5.0M). Under SEC rules, institutional investment managers with over $100M in assets must file Form 13F within 45 days of each quarter-end, disclosing long positions in US-listed equities. The data excludes short positions, most options and foreign holdings, so treat it as a quarterly snapshot rather than a live position.
Other funds holding ZNTL
- 5AM Venture Management, LLC 3.95M sh · $19.15M · Q2 2026
- Decheng Capital LLC 1.32M sh · $6.42M · Q2 2026
- Ishara Investments LP 1.02M sh · $4.97M · Q2 2026
- PFIZER INC 953.83K sh · $3.85M · Q2 2026
- Squadron Capital Management LLC 426.00K sh · $2.07M · Q2 2026
More on Opaleye Management Inc.
FAQ
How long has Opaleye Management Inc. held ZNTL?
Opaleye Management Inc. has disclosed ZNTL holdings in 9 of the last 10 reported quarters, going back to Q1 2024.
What is Opaleye Management Inc.'s current position in ZNTL?
As of Q2 2026, Opaleye Management Inc. holds 1.41M shares of ZNTL (ZENTALIS PHARMACEUTICALS INC), valued at $6.85M, representing 0.62% of its reported portfolio and ranking #30.
Has Opaleye Management Inc. been buying or selling ZNTL?
In the latest 13F filing (Q2 2026), Opaleye Management Inc. held unchanged its position in ZNTL. The position peaked in Q2 2026 at 1.41M shares.
Which other funds hold ZNTL?
Other major institutional holders of ZNTL include 5AM Venture Management, LLC, Decheng Capital LLC, Ishara Investments LP, among 29 funds with disclosed positions.
Where does this data come from?
All figures are computed from SEC Form 13F quarterly filings, which institutional investment managers must file within 45 days of quarter end for long positions of $100,000 or more.